Person · CIK 1192591

Charles J Homcy

Chairman of Pharmaceuticals at BridgeBio Pharma; director at Maze Therapeutics

Earlier: Pliant Therapeutics, Population Health Investment, Portola Pharmaceuticals, Global Blood Therapeutics, MyoKardia, Cephalon, Geron, Cytokinetics, Millennium Pharmaceuticals and Kosan Biosciences

Source: Forms 3, 4, 5 and 144 on SEC EDGAR

Sold on Form 4$54M

Noticed on Form 144$13.9M

Bought on Form 4$0

Companies12

Holdings now

As reported after the latest Form 3, 4 or 5 at each company.

How these figures work

Options and RSUs are from the latest filing that lists them; earlier grants may also be held. Holdings can be out of date when a person stops filing.

Company	Security	Held	Shares or units	As of
BridgeBio Pharma BBIO	Common Stock	Directly	919,876	Jun 22, 2026 · Filing · EDGAR
BridgeBio Pharma BBIO	Stock Option (Right to Buy) exercise $68.92, expires Jun 21, 2036, into Common Stock	Directly	5,277	Jun 22, 2026 · Filing · EDGAR
Maze Therapeutics MAZE	Common Stock	Directly	31,113	May 4, 2026 · Filing · EDGAR
Maze Therapeutics MAZE	Common Stock	By Trust	7,422	Nov 19, 2025 · Filing · EDGAR
Maze Therapeutics MAZE	Stock Option (Right to Buy) exercise $23.58, expires Jun 7, 2036, into Common Stock	Directly	18,000	Jun 8, 2026 · Filing · EDGAR
Pliant Therapeutics	Common Stock	Directly	73,378	Jun 2, 2020 · Filing · EDGAR
Pliant Therapeutics	Stock Option (right to buy) exercise $28.20, expires Jun 28, 2031, into Common Stock	Directly	13,286	Jun 29, 2021 · Filing · EDGAR
Population Health Investment	Class B Ordinary Shares into Class A Ordinary Shares	Directly	43,125	Jan 26, 2021 · Filing · EDGAR
Portola Pharmaceuticals	Common Stock	Directly	112,471	Jan 2, 2019 · Filing · EDGAR
Portola Pharmaceuticals	Common Stock	Charles Homcy Revocable Trust	165,403	Jan 2, 2019 · Filing · EDGAR
Portola Pharmaceuticals	Common Stock	The Charles J. Homcy 2009 Grantor Retained Annuity Trust	20,000	Jan 2, 2019 · Filing · EDGAR
Portola Pharmaceuticals	Common Stock	Through The Charles J. Homcy 2009 Grantor Retained Annuity Trust	20,000	Jun 8, 2018 · Filing · EDGAR
Portola Pharmaceuticals	Stock Options (Right to Buy) exercise $33.59, expires Mar 27, 2029, into Common Stock	Directly	10,000	Mar 28, 2019 · Filing · EDGAR
Global Blood Therapeutics	Common Stock	Directly	21,184	Nov 21, 2017 · Filing · EDGAR
Global Blood Therapeutics	Common Stock	Trust	1,600	Mar 2, 2017 · Filing · EDGAR
Global Blood Therapeutics	Common Stock	By Charles Homcy Revocable Trust	1,600	Dec 31, 2017 · Filing · EDGAR
Global Blood Therapeutics	COMMON STOCK	By Charles Homcy Irrevocable Trust	1,600	Dec 31, 2016 · Filing · EDGAR
Global Blood Therapeutics	Common Stock	By Trust	1,600	Oct 26, 2017 · Filing · EDGAR
Global Blood Therapeutics	Stock Option (right to buy) exercise $42.25, expires Jun 19, 2028, into Common Stock	Directly	15,000	Jun 20, 2018 · Filing · EDGAR
MyoKardia	Common Stock	Directly	6,496	Nov 29, 2016 · Filing · EDGAR
MyoKardia	Common Stock	Trust	5,442	Oct 28, 2015 · Filing · EDGAR
Geron	Common Stock	Directly	62,751	May 11, 2011 · Filing · EDGAR
Millennium Pharmaceuticals	Common stock	by 401(k) plan	1,119	Feb 17, 2004 · Filing · EDGAR

Sold and noticed by quarter

Sold (Form 4) Noticed (Form 144) Bought (Form 4)

Quarterly totals as a table

Quarter	Sold (Form 4)	Noticed (Form 144)
Q3 2025	$13.9M	$13.9M
Q4 2020	$420K	Not machine-readable
Q3 2020	$4M	Not machine-readable
Q1 2020	$1.1M	Not machine-readable
Q4 2018	$1.2M	Not machine-readable
Q4 2017	$2.4M	Not machine-readable
Q2 2017	$9.1M	Not machine-readable
Q1 2017	$2.9M	Not machine-readable
Q3 2015	$4.7M	Not machine-readable
Q2 2015	$4.4M	Not machine-readable
Q1 2015	$2.8M	Not machine-readable
Q4 2013	$2.3M	Not machine-readable
Q4 2007	$936K	Not machine-readable
Q3 2007	$1.2M	Not machine-readable
Q1 2007	$312K	Not machine-readable
Q4 2006	$229K	Not machine-readable
Q1 2004	$1.7M	Not machine-readable
Q3 2003	$457K	Not machine-readable

Form 144 notices went onto EDGAR as structured data on April 13, 2023. Earlier notices were filed on paper and cannot be read here, so those quarters show no noticed amount.

Planned sales (Form 144) and the sales that followed

Each Form 144 notice of a planned sale, grouped by broker and 10b5-1 plan, with the Form 4 sales we matched to it.

How we match

A Form 144 is a notice of a planned sale by an affiliate. SEC Tracker matches each notice to Form 4 sales by the same person at the same company within 90 days of the notice, up to the shares noticed. The match is our inference, not something either filing states.

Notice date	Noticed	Planned sale	Outcome	Links
BridgeBio Pharma BBIO · Morgan Stanley Smith Barney · 10b5-1 plan adopted May 8, 2025 · 2 notices
Aug 11, 2025	50,000 · ~$2.4M	Aug 11, 2025	Sold as noticed Sold 50,000 at $48.00 on Aug 11 · $2.4M Form 4	Filing · EDGAR
Aug 8, 2025	250,000 · ~$11.5M	Aug 8, 2025	Sold as noticed Sold 250,000 in 2 sales, Aug 8 to Aug 8 · $11.5M Form 4	Filing · EDGAR
Sales without a matching Form 144 · 53 sales No matching Form 144 found. Not every sale needs one: small sales and sales by people who are not affiliates are exempt.
—	—	—	Notice not machine-readable BridgeBio Pharma (BBIO): Sold 10,256 at $41.00 on Oct 16, 2020 · $420K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable BridgeBio Pharma (BBIO): Sold 10,000 at $38.00 on Sep 30, 2020 · $380K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable BridgeBio Pharma (BBIO): Sold 18,200 at $37.50 on Sep 29, 2020 · $683K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable BridgeBio Pharma (BBIO): Sold 15,396 at $37.47 on Sep 25, 2020 · $577K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable BridgeBio Pharma (BBIO): Sold 65,661 at $36.68 on Sep 25, 2020 · $2.4M (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable BridgeBio Pharma (BBIO): Sold 20,000 at $36.00 on Feb 10, 2020 · $720K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable BridgeBio Pharma (BBIO): Sold 10,000 at $35.00 on Jan 14, 2020 · $350K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Portola Pharmaceuticals: Sold 700 at $19.20 on Dec 17, 2018 · $13K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Portola Pharmaceuticals: Sold 63,518 at $18.60 on Dec 17, 2018 · $1.2M (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Global Blood Therapeutics: Sold 15,600 at $34.09 on Oct 27, 2017 · $532K	Filing · EDGAR
—	—	—	Notice not machine-readable Global Blood Therapeutics: Sold 54,400 at $33.93 on Oct 26, 2017 · $1.8M	Filing · EDGAR
—	—	—	Notice not machine-readable Global Blood Therapeutics: Sold 0 at $30.86 on Oct 4, 2017	Filing · EDGAR
—	—	—	Notice not machine-readable Global Blood Therapeutics: Sold 0 at $30.86 on Oct 4, 2017	Filing · EDGAR
—	—	—	Notice not machine-readable Global Blood Therapeutics: Sold 0 at $30.38 on Oct 4, 2017	Filing · EDGAR
—	—	—	Notice not machine-readable Global Blood Therapeutics: Sold 0 at $30.38 on Oct 4, 2017	Filing · EDGAR
—	—	—	Notice not machine-readable Global Blood Therapeutics: Sold 0 at $30.17 on Oct 3, 2017	Filing · EDGAR
—	—	—	Notice not machine-readable Global Blood Therapeutics: Sold 0 at $30.17 on Oct 3, 2017	Filing · EDGAR
—	—	—	Notice not machine-readable Portola Pharmaceuticals: Sold 120,803 at $53.06 on Jun 23, 2017 · $6.4M (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Global Blood Therapeutics: Sold 31,742 at $27.64 on Jun 2, 2017 · $877K	Filing · EDGAR
—	—	—	Notice not machine-readable Global Blood Therapeutics: Sold 49,959 at $26.92 on Jun 2, 2017 · $1.3M	Filing · EDGAR
—	—	—	Notice not machine-readable Global Blood Therapeutics: Sold 18,299 at $26.58 on Jun 1, 2017 · $486K	Filing · EDGAR
—	—	—	Notice not machine-readable Portola Pharmaceuticals: Sold 50,000 at $40.06 on Mar 15, 2017 · $2M (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Global Blood Therapeutics: Sold 0 at $25.50 on Mar 2, 2017	Filing · EDGAR
—	—	—	Notice not machine-readable Global Blood Therapeutics: Sold 0 at $25.50 on Mar 2, 2017	Filing · EDGAR
—	—	—	Notice not machine-readable Portola Pharmaceuticals: Sold 25,000 at $37.50 on Mar 1, 2017 · $938K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Global Blood Therapeutics: Sold 0 on Nov 14, 2016	Filing · EDGAR
—	—	—	Notice not machine-readable Global Blood Therapeutics: Sold 0 on Nov 14, 2016	Filing · EDGAR
—	—	—	Notice not machine-readable Portola Pharmaceuticals: Sold 20,000 at $57.50 on Sep 18, 2015 · $1.2M (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Portola Pharmaceuticals: Sold 20,067 at $55.00 on Sep 18, 2015 · $1.1M (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Portola Pharmaceuticals: Sold 50,000 at $48.00 on Jul 13, 2015 · $2.4M (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Portola Pharmaceuticals: Sold 200 at $44.92 on Jun 29, 2015 · $9K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Portola Pharmaceuticals: Sold 27,876 at $44.24 on Jun 29, 2015 · $1.2M (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Portola Pharmaceuticals: Sold 71,924 at $43.60 on Jun 29, 2015 · $3.1M (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Portola Pharmaceuticals: Sold 20,000 at $40.00 on Feb 23, 2015 · $800K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Portola Pharmaceuticals: Sold 20,000 at $36.00 on Feb 17, 2015 · $720K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Portola Pharmaceuticals: Sold 20,000 at $34.05 on Feb 13, 2015 · $681K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Portola Pharmaceuticals: Sold 19,700 at $30.00 on Jan 28, 2015 · $591K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Portola Pharmaceuticals: Sold 300 at $30.00 on Jan 27, 2015 · $9K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Portola Pharmaceuticals: Sold 95,962 at $23.75 on Oct 22, 2013 · $2.3M	Filing · EDGAR
—	—	—	Notice not machine-readable Millennium Pharmaceuticals: Sold 59,238 at $15.81 on Dec 11, 2007 · $936K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Millennium Pharmaceuticals: Sold 40,000 at $10.68 on Sep 19, 2007 · $427K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Millennium Pharmaceuticals: Sold 40,000 at $10.33 on Sep 18, 2007 · $413K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Millennium Pharmaceuticals: Sold 10,000 at $9.76 on Sep 17, 2007 · $98K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Millennium Pharmaceuticals: Sold 30,000 at $10.20 on Sep 4, 2007 · $306K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Millennium Pharmaceuticals: Sold 27,774 at $11.24 on Feb 16, 2007 · $312K	Filing · EDGAR
—	—	—	Notice not machine-readable Millennium Pharmaceuticals: Sold 11,046 at $11.41 on Nov 21, 2006 · $126K	Filing · EDGAR
—	—	—	Notice not machine-readable Millennium Pharmaceuticals: Sold 2,000 at $11.44 on Nov 21, 2006 · $23K	Filing · EDGAR
—	—	—	Notice not machine-readable Millennium Pharmaceuticals: Sold 2,800 at $11.45 on Nov 21, 2006 · $32K	Filing · EDGAR
—	—	—	Notice not machine-readable Millennium Pharmaceuticals: Sold 4,154 at $11.46 on Nov 21, 2006 · $48K	Filing · EDGAR
—	—	—	Notice not machine-readable Millennium Pharmaceuticals: Sold 40,255 at $19.17 on Feb 17, 2004 · $772K	Filing · EDGAR
—	—	—	Notice not machine-readable Millennium Pharmaceuticals: Sold 50,000 at $18.10 on Feb 2, 2004 · $905K	Filing · EDGAR
—	—	—	Notice not machine-readable Millennium Pharmaceuticals: Sold 24,879 at $15.30 on Sep 5, 2003 · $381K	Filing · EDGAR
—	—	—	Notice not machine-readable Millennium Pharmaceuticals: Sold 5,121 at $14.92 on Sep 4, 2003 · $76K	Filing · EDGAR

Every transaction, by company

Each Form 3, 4 and 5 transaction in plain words, newest first.

How these figures work

Values are shares times the price each filing states; grants, exercises and gifts usually state no price. Held after is what the filing reports was held once the transaction was done, directly or through the named holder.

BridgeBio Pharma BBIO Chairman of Pharmaceuticals · filings 2019 to 2026 · sold $19.5M · $13.9M noticed on Form 144

Date	Transaction	Shares	Price	Value	Held after	Source
Jun 22, 2026	Grant or award from the company	+3,990			919,876 direct	Filing · EDGAR
Jun 22, 2026	Grant or award from the company Stock Option (Right to Buy)	+5,277			5,277 direct	Filing · EDGAR
Jun 20, 2026	Shares withheld for tax or exercise price	−788	$66.27	$52K	915,886 direct	Filing · EDGAR
Aug 11, 2025	Sale under a 10b5-1 plan	−50,000	$48.00	$2.4M	916,674 direct	Filing · EDGAR
Aug 8, 2025	Sale under a 10b5-1 plan	−191,662	$45.87	$8.8M	1,025,012 direct	Filing · EDGAR
Aug 8, 2025	Sale under a 10b5-1 plan	−58,338	$46.64	$2.7M	966,674 direct	Filing · EDGAR
Jun 27, 2025	Gift	−20,000			1,216,674 direct	Filing · EDGAR
Jun 20, 2025	Grant or award from the company	+6,589			1,236,674 direct	Filing · EDGAR
Jun 20, 2025	Grant or award from the company Stock Option (Right to Buy)	+8,425			8,425 direct	Filing · EDGAR
Jun 21, 2024	Grant or award from the company Stock Option (Right to Buy)	+26,014			26,014 direct	Filing · EDGAR
Feb 16, 2024	Option or RSU exercised or converted	+3,760			1,231,594 direct	Filing · EDGAR
Feb 16, 2024	Shares withheld for tax or exercise price	−1,509	$37.21	$56K	1,230,085 direct	Filing · EDGAR
Feb 16, 2024	Option or RSU exercised or converted Restricted Stock Units	−3,760			0 direct	Filing · EDGAR
Nov 16, 2023	Option or RSU exercised or converted	+3,760			1,228,297 direct	Filing · EDGAR
Nov 16, 2023	Shares withheld for tax or exercise price	−1,301	$28.86	$38K	1,226,996 direct	Filing · EDGAR
Nov 16, 2023	Option or RSU exercised or converted Restricted Stock Units	−3,760			3,760 direct	Filing · EDGAR
Aug 16, 2023	Option or RSU exercised or converted	+3,760			1,225,838 direct	Filing · EDGAR
Aug 16, 2023	Shares withheld for tax or exercise price	−1,301	$29.80	$39K	1,224,537 direct	Filing · EDGAR
Aug 16, 2023	Option or RSU exercised or converted Restricted Stock Units	−3,760			7,520 direct	Filing · EDGAR
Jun 21, 2023	Grant or award from the company Stock Option (right to buy)	+51,501			51,501 direct	Filing · EDGAR
May 16, 2023	Option or RSU exercised or converted	+3,759			1,222,127 direct	Filing · EDGAR
May 16, 2023	Shares withheld for tax or exercise price	−1,300	$14.09	$18K	1,220,827 direct	Filing · EDGAR
May 16, 2023	Option or RSU exercised or converted Restricted Stock Units	−3,759			11,280 direct	Filing · EDGAR
Feb 16, 2023	Option or RSU exercised or converted	+3,760			1,219,902 direct	Filing · EDGAR
Feb 16, 2023	Shares withheld for tax or exercise price	−1,534	$12.64	$19K	1,218,368 direct	Filing · EDGAR
Feb 16, 2023	Option or RSU exercised or converted Restricted Stock Units	−3,760			15,039 direct	Filing · EDGAR
Nov 16, 2022	Option or RSU exercised or converted	+3,760			1,215,552 direct	Filing · EDGAR
Nov 16, 2022	Shares withheld for tax or exercise price	−1,301	$9.64	$13K	1,214,251 direct	Filing · EDGAR
Nov 16, 2022	Option or RSU exercised or converted Restricted Stock Units	−3,760			18,799 direct	Filing · EDGAR
Aug 16, 2022	Option or RSU exercised or converted	+3,760			1,210,742 direct	Filing · EDGAR
Aug 16, 2022	Shares withheld for tax or exercise price	−1,287	$11.08	$14K	1,209,455 direct	Filing · EDGAR
Aug 16, 2022	Option or RSU exercised or converted Restricted Stock Units	−3,760			22,559 direct	Filing · EDGAR
Jun 22, 2022	Grant or award from the company Stock Option (right to buy)	+104,921			104,921 direct	Filing · EDGAR
May 16, 2022	Option or RSU exercised or converted	+3,759			1,208,523 direct	Filing · EDGAR
May 16, 2022	Shares withheld for tax or exercise price	−1,541	$6.74	$10K	1,206,982 direct	Filing · EDGAR
May 16, 2022	Option or RSU exercised or converted Restricted Stock Units	−3,759			26,319 direct	Filing · EDGAR
Feb 28, 2022	Grant or award from the company Restricted Stock Units	+30,078			30,078 direct	Filing · EDGAR
Dec 2, 2021	Grant or award from the company Stock Option (right to buy)	+55,011			55,011 direct	Filing · EDGAR
Jun 17, 2021	Grant or award from the company Stock Option (right to buy)	+38,895			38,895 direct	Filing · EDGAR
Mar 1, 2021	Grant or award from the company	+1,521			1,205,288 direct	Filing · EDGAR
Mar 1, 2021	Shares withheld for tax or exercise price	−524	$71.91	$38K	1,204,764 direct	Filing · EDGAR
Oct 16, 2020	Option or RSU exercised or converted	+10,256	$17.00	$174K	1,214,023 direct	Filing · EDGAR
Oct 16, 2020	Sale under a 10b5-1 plan	−10,256	$41.00	$420K	1,203,767 direct	Filing · EDGAR
Oct 16, 2020	Option or RSU exercised or converted Stock Option (Right to Buy)	−10,256			260,207 direct	Filing · EDGAR
Sep 30, 2020	Option or RSU exercised or converted	+10,000	$17.00	$170K	1,213,767 direct	Filing · EDGAR
Sep 30, 2020	Sale under a 10b5-1 plan	−10,000	$38.00	$380K	1,203,767 direct	Filing · EDGAR
Sep 30, 2020	Option or RSU exercised or converted Stock Option (Right to Buy)	−10,000			270,463 direct	Filing · EDGAR
Sep 29, 2020	Sale under a 10b5-1 plan	−18,200	$37.50	$683K	1,203,767 direct	Filing · EDGAR
Sep 25, 2020	Sale under a 10b5-1 plan	−65,661	$36.68	$2.4M	1,237,363 direct	Filing · EDGAR
Sep 25, 2020	Sale under a 10b5-1 plan	−15,396	$37.47	$577K	1,221,967 direct	Filing · EDGAR
Jun 2, 2020	Grant or award from the company Stock Option (right to buy)	+112,422			112,422 direct	Filing · EDGAR
Apr 3, 2020	Gift	−40,000			1,302,291 direct	Filing · EDGAR
Feb 10, 2020	Sale under a 10b5-1 plan	−20,000	$36.00	$720K	1,342,291 direct	Filing · EDGAR
Jan 14, 2020	Option or RSU exercised or converted	+10,000	$17.00	$170K	1,372,291 direct	Filing · EDGAR
Jan 14, 2020	Sale under a 10b5-1 plan	−10,000	$35.00	$350K	1,362,291 direct	Filing · EDGAR
Jan 14, 2020	Option or RSU exercised or converted Stock Option (Right to Buy)	−10,000			280,463 direct	Filing · EDGAR
Dec 12, 2019	Grant or award from the company Stock Option (right to buy)	+82,878			82,878 direct	Filing · EDGAR
Jul 1, 2019	Option or RSU exercised or converted	+47,165	$0.00	$47	47,165 direct	Filing · EDGAR
Jul 1, 2019	Option or RSU exercised or converted	+132,317	$0.00	$132	179,482 direct	Filing · EDGAR
Jul 1, 2019	Option or RSU exercised or converted	+66,729	$0.00	$67	246,211 direct	Filing · EDGAR

9 earlier transactions are in the filing list below.

Maze Therapeutics MAZE Director · filings 2025 to 2026

Date	Transaction	Shares	Price	Held after	Source
Jun 8, 2026	Grant or award from the company Stock Option (Right to Buy)	+18,000		18,000 direct	Filing · EDGAR
May 4, 2026	Gift	−7,422		31,113 direct	Filing · EDGAR
Nov 19, 2025	Other acquisition or disposition (see the filing)	+1,489		31,113 direct	Filing · EDGAR
Oct 23, 2025	Gift	−28,423		29,624 direct	Filing · EDGAR
Sep 22, 2025	Grant or award from the company Stock Option (Right to Buy)	+18,000		18,000 direct	Filing · EDGAR
Feb 3, 2025	Derivative converted	+8,807		37,330 direct	Filing · EDGAR
Feb 3, 2025	Derivative converted	+20,717		58,047 direct	Filing · EDGAR
Feb 3, 2025	Derivative converted	+7,422		7,422 By Trust	Filing · EDGAR
Feb 3, 2025	Derivative converted Series B Preferred Stock	−72,727		0 direct	Filing · EDGAR
Feb 3, 2025	Derivative converted Series C Preferred Stock	−169,405		0 direct	Filing · EDGAR
Feb 3, 2025	Derivative converted Series D-1 Preferred Stock	−71,564		0 By Trust	Filing · EDGAR
Dec 9, 2024	Grant or award from the company Stock Option (Right to Buy)	+80,385		80,385 direct	Filing · EDGAR
Dec 9, 2024	Returned to the company Stock Option (Right to Buy)	−80,385		0 direct	Filing · EDGAR
Dec 9, 2024	Grant or award from the company Stock Option (Right to Buy)	+5,704		5,704 direct	Filing · EDGAR
Dec 9, 2024	Returned to the company Stock Option (Right to Buy)	−5,704		0 direct	Filing · EDGAR
Dec 9, 2024	Grant or award from the company Stock Option (Right to Buy)	+46,675		46,675 direct	Filing · EDGAR
Dec 9, 2024	Returned to the company Stock Option (Right to Buy)	−46,675		0 direct	Filing · EDGAR
Dec 9, 2024	Grant or award from the company Stock Option (Right to Buy)	+45,638		45,638 direct	Filing · EDGAR
Nov 26, 2024	Derivative converted Series D-1 Preferred Stock	+71,564		7,422 By Trust	Filing · EDGAR
Nov 26, 2024	Derivative converted 8% Convertible Note due 2026		$78,961.64	71,564 By Trust	Filing · EDGAR

Pliant Therapeutics Director · filings 2020 to 2021

Date	Transaction	Shares	Price	Value	Held after	Source
Jun 29, 2021	Grant or award from the company Stock Option (right to buy)	+13,286			13,286 direct	Filing · EDGAR

Population Health Investment Director · filings 2020 to 2021

Date	Transaction	Shares	Price	Value	Held after	Source
Jan 26, 2021	Other acquisition or disposition (see the filing) Class B Ordinary Shares	+43,125	$250.00	$10.8M	43,125 direct	Filing · EDGAR

Portola Pharmaceuticals Other · filings 2013 to 2019 · sold $24.7M

Date	Transaction	Shares	Price	Value	Held after	Source
Mar 28, 2019	Grant or award from the company Stock Options (Right to Buy)	+10,000			10,000 direct	Filing · EDGAR
Jan 2, 2019	Option or RSU exercised or converted	+45,923	$5.10	$234K	165,403 Charles Homcy Revocable Trust	Filing · EDGAR
Jan 2, 2019	Option or RSU exercised or converted Stock Option (Right to Buy)	−19,607			0 direct	Filing · EDGAR
Jan 2, 2019	Option or RSU exercised or converted Stock Option (Right to Buy)	−14,835			0 direct	Filing · EDGAR
Jan 2, 2019	Option or RSU exercised or converted Stock Option (Right to Buy)	−11,481			0 direct	Filing · EDGAR
Dec 19, 2018	Option or RSU exercised or converted	+25,782	$4.10	$106K	119,480 Charles Homcy Revocable Trust	Filing · EDGAR
Dec 19, 2018	Option or RSU exercised or converted Stock Option (Right to Buy)	−25,782			0 direct	Filing · EDGAR
Dec 17, 2018	Option or RSU exercised or converted	+64,218	$4.10	$263K	176,689 direct	Filing · EDGAR
Dec 17, 2018	Sale under a 10b5-1 plan	−63,518	$18.60	$1.2M	113,171 direct	Filing · EDGAR
Dec 17, 2018	Sale under a 10b5-1 plan	−700	$19.20	$13K	112,471 direct	Filing · EDGAR
Dec 17, 2018	Option or RSU exercised or converted Stock Option (Right to Buy)	−24,390			0 direct	Filing · EDGAR
Dec 17, 2018	Option or RSU exercised or converted Stock Option (Right to Buy)	−39,828			25,782 direct	Filing · EDGAR
Nov 14, 2018	Option or RSU exercised or converted	+93,698	$4.10	$384K	93,698 Charles Homcy Revocable Trust	Filing · EDGAR
Nov 14, 2018	Option or RSU exercised or converted Employee Stock Option (Right to Buy)	−93,698			65,610 direct	Filing · EDGAR
Jun 8, 2018	Grant or award from the company	+3,000			115,471 direct	Filing · EDGAR
Jun 8, 2018	Grant or award from the company Stock Option (Right to Buy)	+6,000			6,000 direct	Filing · EDGAR
Jun 23, 2017	Option or RSU exercised or converted	+120,803	$5.00	$604K	120,803 direct	Filing · EDGAR
Jun 23, 2017	Sale under a 10b5-1 plan	−120,803	$53.06	$6.4M	0 direct	Filing · EDGAR
Jun 23, 2017	Option or RSU exercised or converted Stock Option (Right to Buy)	−120,803			0 direct	Filing · EDGAR
Jun 16, 2017	Grant or award from the company	+3,000			3,000 direct	Filing · EDGAR
Jun 16, 2017	Grant or award from the company Stock Option (Right to Buy)	+6,000			6,000 direct	Filing · EDGAR
Mar 15, 2017	Option or RSU exercised or converted	+50,000	$5.00	$250K	50,000 direct	Filing · EDGAR
Mar 15, 2017	Sale under a 10b5-1 plan	−50,000	$40.06	$2M	0 direct	Filing · EDGAR
Mar 15, 2017	Option or RSU exercised or converted Stock Option (Right to Buy)	−50,000			120,803 direct	Filing · EDGAR
Mar 1, 2017	Option or RSU exercised or converted	+25,000	$5.00	$125K	25,000 direct	Filing · EDGAR
Mar 1, 2017	Sale under a 10b5-1 plan	−25,000	$37.50	$938K	0 direct	Filing · EDGAR
Mar 1, 2017	Option or RSU exercised or converted Stock Option (Right to Buy)	−25,000			170,803 direct	Filing · EDGAR
Jun 17, 2016	Grant or award from the company	+3,000			3,000 direct	Filing · EDGAR
Jun 17, 2016	Grant or award from the company Stock Option (Right to Buy)	+6,000			6,000 direct	Filing · EDGAR
Sep 18, 2015	Option or RSU exercised or converted	+20,067	$3.30	$66K	20,067 direct	Filing · EDGAR
Sep 18, 2015	Sale under a 10b5-1 plan	−20,067	$55.00	$1.1M	0 direct	Filing · EDGAR
Sep 18, 2015	Option or RSU exercised or converted	+20,000	$5.00	$100K	20,000 direct	Filing · EDGAR
Sep 18, 2015	Sale under a 10b5-1 plan	−20,000	$57.50	$1.2M	0 direct	Filing · EDGAR
Sep 18, 2015	Option or RSU exercised or converted Stock Option (Right to Buy)	−20,067			0 direct	Filing · EDGAR
Sep 18, 2015	Option or RSU exercised or converted Stock Option (Right to Buy)	−20,000			0 direct	Filing · EDGAR
Jul 13, 2015	Option or RSU exercised or converted	+50,000	$3.30	$165K	50,000 direct	Filing · EDGAR
Jul 13, 2015	Sale under a 10b5-1 plan	−50,000	$48.00	$2.4M	0 direct	Filing · EDGAR
Jul 13, 2015	Option or RSU exercised or converted Stock Option (Right to Buy)	−50,000			20,067 direct	Filing · EDGAR
Jun 29, 2015	Option or RSU exercised or converted	+100,000	$3.30	$330K	100,000 direct	Filing · EDGAR
Jun 29, 2015	Sale under a 10b5-1 plan	−71,924	$43.60	$3.1M	28,076 direct	Filing · EDGAR
Jun 29, 2015	Sale under a 10b5-1 plan	−27,876	$44.24	$1.2M	200 direct	Filing · EDGAR
Jun 29, 2015	Sale under a 10b5-1 plan	−200	$44.92	$9K	0 direct	Filing · EDGAR
Jun 29, 2015	Option or RSU exercised or converted Stock Option (Right to Buy)	−100,000			70,067 direct	Filing · EDGAR
Jun 16, 2015	Grant or award from the company Stock Option (Right to Buy)	+10,000			10,000 direct	Filing · EDGAR
Feb 23, 2015	Option or RSU exercised or converted	+20,000	$3.30	$66K	20,000 direct	Filing · EDGAR
Feb 23, 2015	Sale under a 10b5-1 plan	−20,000	$40.00	$800K	0 direct	Filing · EDGAR
Feb 23, 2015	Option or RSU exercised or converted Stock Option (Right to Buy)	−20,000			190,067 direct	Filing · EDGAR
Feb 17, 2015	Option or RSU exercised or converted	+20,000	$3.30	$66K	20,000 direct	Filing · EDGAR
Feb 17, 2015	Sale under a 10b5-1 plan	−20,000	$36.00	$720K	0 direct	Filing · EDGAR
Feb 17, 2015	Option or RSU exercised or converted Stock Option (Right to Buy)	−20,000			190,067 direct	Filing · EDGAR
Feb 13, 2015	Option or RSU exercised or converted	+20,000	$3.30	$66K	20,000 direct	Filing · EDGAR
Feb 13, 2015	Sale under a 10b5-1 plan	−20,000	$34.05	$681K	0 direct	Filing · EDGAR
Feb 13, 2015	Option or RSU exercised or converted Stock Option (Right to Buy)	−20,000			210,067 direct	Filing · EDGAR
Jan 28, 2015	Option or RSU exercised or converted	+19,700	$3.30	$65K	19,700 direct	Filing · EDGAR
Jan 28, 2015	Sale under a 10b5-1 plan	−19,700	$30.00	$591K	0 direct	Filing · EDGAR
Jan 28, 2015	Option or RSU exercised or converted Stock Option (Right to Buy)	−19,700			230,067 direct	Filing · EDGAR
Jan 27, 2015	Option or RSU exercised or converted	+300	$3.30	$990	300 direct	Filing · EDGAR
Jan 27, 2015	Sale under a 10b5-1 plan	−300	$30.00	$9K	0 direct	Filing · EDGAR
Jan 27, 2015	Option or RSU exercised or converted Stock Option (Right to Buy)	−300			249,767 direct	Filing · EDGAR
Jun 27, 2014	Grant or award from the company Stock Option (Right to Buy)	+10,000			10,000 direct	Filing · EDGAR

4 earlier transactions are in the filing list below.

Global Blood Therapeutics Director · filings 2015 to 2018 · sold $5.1M

Date	Transaction	Shares	Price	Value	Held after	Source
Jun 20, 2018	Grant or award from the company Stock Option (right to buy)	+15,000			15,000 direct	Filing · EDGAR
Nov 28, 2017	Other acquisition or disposition (see the filing)	+6,359			79,229 By Charles Homcy Revocable Trust	Filing · EDGAR
Nov 21, 2017	Other acquisition or disposition (see the filing)	−6,359			21,184 direct	Filing · EDGAR
Oct 27, 2017	Open-market or private sale	−15,600	$34.09	$532K	67,728 direct	Filing · EDGAR
Oct 26, 2017	Other acquisition or disposition (see the filing)	−70,000			72,870 By Charles Homcy Revocable Trust	Filing · EDGAR
Oct 26, 2017	Open-market or private sale	−54,400	$33.93	$1.8M	83,328 direct	Filing · EDGAR
Oct 4, 2017	Open-market or private sale	−0	$30.38		0 See Footnote	Filing · EDGAR
Oct 4, 2017	Open-market or private sale	−0	$30.38		0 See Footnote	Filing · EDGAR
Oct 4, 2017	Open-market or private sale	−0	$30.86		0 See Footnote	Filing · EDGAR
Oct 4, 2017	Open-market or private sale	−0	$30.86		0 See Footnote	Filing · EDGAR
Oct 3, 2017	Open-market or private sale	−0	$30.17		0 See Footnote	Filing · EDGAR
Oct 3, 2017	Open-market or private sale	−0	$30.17		0 See Footnote	Filing · EDGAR
Sep 26, 2017	Other acquisition or disposition (see the filing)	+2,563			142,870 By Charles Homcy Revocable Trust	Filing · EDGAR
Sep 21, 2017	Other acquisition or disposition (see the filing)	−2,563			27,543 direct	Filing · EDGAR
Jul 28, 2017	Other acquisition or disposition (see the filing)	+112,685			140,307 By Charles Homcy Revocable Trust	Filing · EDGAR
Jun 21, 2017	Other acquisition or disposition (see the filing)	+1,504			27,622 By Charles Homcy Revocable Trust	Filing · EDGAR
Jun 20, 2017	Grant or award from the company Stock Option (right to buy)	+15,000			15,000 direct	Filing · EDGAR
Jun 14, 2017	Other acquisition or disposition (see the filing)	−1,504			30,106 direct	Filing · EDGAR
Jun 2, 2017	Open-market or private sale	−49,959	$26.92	$1.3M	169,470 direct	Filing · EDGAR
Jun 2, 2017	Open-market or private sale	−31,742	$27.64	$877K	137,728 direct	Filing · EDGAR
Jun 1, 2017	Open-market or private sale	−18,299	$26.58	$486K	219,429 direct	Filing · EDGAR
May 25, 2017	Other acquisition or disposition (see the filing)	+3,277			26,118 By Charles Homcy Revocable Trust	Filing · EDGAR
May 17, 2017	Other acquisition or disposition (see the filing)	−3,277			31,610 direct	Filing · EDGAR
Apr 13, 2017	Other acquisition or disposition (see the filing)	+7,798			22,841 By Charles Homcy Revocable Trust	Filing · EDGAR
Apr 6, 2017	Other acquisition or disposition (see the filing)	−7,798			34,877 direct	Filing · EDGAR
Mar 2, 2017	Open-market or private sale	−0	$25.50		0 See Footnote	Filing · EDGAR
Mar 2, 2017	Open-market or private sale	−0	$25.50		0 See Footnote	Filing · EDGAR
Dec 23, 2016	Other acquisition or disposition (see the filing)	−10,432			212,685 direct	Filing · EDGAR
Dec 23, 2016	Other acquisition or disposition (see the filing)	+10,432			15,043 By Charles Homcy Revocable Trust	Filing · EDGAR
Dec 16, 2016	Other acquisition or disposition (see the filing)	+10,432			237,728 direct	Filing · EDGAR
Nov 23, 2016	Gift	−10,000			4,611 By Charles Homcy Revocable Trust	Filing · EDGAR
Nov 14, 2016	Other acquisition or disposition (see the filing)	−14,611			223,117 direct	Filing · EDGAR
Nov 14, 2016	Other acquisition or disposition (see the filing)	−14,611			14,611 By Charles Homcy Revocable Trust	Filing · EDGAR
Nov 14, 2016	Open-market or private sale	−0			0 See Footnote	Filing · EDGAR
Nov 14, 2016	Open-market or private sale	−0			0 See Footnote	Filing · EDGAR
Nov 3, 2016	Other acquisition or disposition (see the filing)	+14,611			227,296 direct	Filing · EDGAR
Nov 3, 2016	Other acquisition or disposition (see the filing)	−0			0 See Footnote	Filing · EDGAR
Jun 16, 2016	Grant or award from the company Stock Option (right to buy)	+15,000			15,000 direct	Filing · EDGAR
Aug 11, 2015	Grant or award from the company Stock Option (right to buy)	+15,000			15,000 direct	Filing · EDGAR

MyoKardia Director · filings 2015 to 2016

Date	Transaction	Shares	Price	Value	Held after	Source
Nov 29, 2016	Other acquisition or disposition (see the filing)	−0			0 See Footnote	Filing · EDGAR
Jun 7, 2016	Grant or award from the company Stock Option (Right to Buy)	+11,000			11,000 direct	Filing · EDGAR

Cephalon Director · filings 2011 to 2011

Date	Transaction	Shares	Held after	Source
Oct 14, 2011	Returned to the company Non-Qualified Stock Option	−15,000	0 direct	Filing · EDGAR
Oct 14, 2011	Returned to the company Non-Qualified Stock Option	−15,000	0 direct	Filing · EDGAR
May 10, 2011	Grant or award from the company Non-Qualified Stock Option	+15,000	15,000 direct	Filing · EDGAR
Mar 10, 2011	Grant or award from the company Non-Qualified Stock Option	+15,000	15,000 direct	Filing · EDGAR

Geron Director · filings 2005 to 2011

Date	Transaction	Shares	Price	Value	Held after	Source
May 11, 2011	Grant or award from the company	+5,000			120,251 direct	Filing · EDGAR
May 11, 2011	Returned to the company	−57,500			62,751 direct	Filing · EDGAR
May 11, 2011	Grant or award from the company Stock Option (right to buy)	+10,000			10,000 direct	Filing · EDGAR
Jul 9, 2010	Grant or award from the company	+9,000			79,251 direct	Filing · EDGAR
Jul 9, 2010	Grant or award from the company	+9,000			88,251 direct	Filing · EDGAR
Jul 9, 2010	Grant or award from the company	+9,000			97,251 direct	Filing · EDGAR
Jul 9, 2010	Grant or award from the company	+18,000			115,251 direct	Filing · EDGAR
May 19, 2010	Grant or award from the company	+5,000			70,251 direct	Filing · EDGAR
May 19, 2010	Grant or award from the company Stock Option (right to buy)	+10,000			10,000 direct	Filing · EDGAR
May 29, 2009	Grant or award from the company	+3,067	$6.52	$20K	40,251 direct	Filing · EDGAR
May 29, 2009	Grant or award from the company	+5,000			45,251 direct	Filing · EDGAR
May 29, 2009	Grant or award from the company	+20,000			65,251 direct	Filing · EDGAR
May 29, 2009	Grant or award from the company Stock Option (right to buy)	+10,000	$6.52	$65K	95,000 direct	Filing · EDGAR
May 28, 2008	Grant or award from the company	+5,038	$3.97	$20K	32,184 direct	Filing · EDGAR
May 28, 2008	Grant or award from the company	+5,000			37,184 direct	Filing · EDGAR
May 28, 2008	Grant or award from the company Stock Option (right to buy)	+10,000	$3.97	$40K	85,000 direct	Filing · EDGAR
May 23, 2007	Grant or award from the company	+2,146	$9.32	$20K	22,146 direct	Filing · EDGAR
May 23, 2007	Grant or award from the company	+5,000			27,146 direct	Filing · EDGAR
May 23, 2007	Grant or award from the company Stock Option (right to buy)	+10,000	$9.32	$93K	75,000 direct	Filing · EDGAR
Jan 3, 2007	Grant or award from the company	+20,000			20,000 direct	Filing · EDGAR
May 24, 2006	Grant or award from the company Stock Option (right to buy)	+20,000	$6.63	$133K	65,000 direct	Filing · EDGAR

Cytokinetics Director · filings 2004 to 2008

Date	Transaction	Shares	Held after	Source
May 22, 2008	Grant or award from the company Non-Qualified Stock Option (right to buy)	+15,000	15,000 direct	Filing · EDGAR
May 24, 2007	Grant or award from the company Non-Qualified Stock Option (right to buy)	+10,000	10,000 direct	Filing · EDGAR
May 25, 2006	Grant or award from the company Non-Qualified Stock Option (right to buy)	+7,500	7,500 direct	Filing · EDGAR
May 19, 2005	Grant or award from the company Non-Qualified Stock Option (right to buy)	+7,500	7,500 direct	Filing · EDGAR

Millennium Pharmaceuticals Director · filings 2003 to 2008 · sold $4.9M

Date	Transaction	Shares	Price	Value	Held after	Source
May 14, 2008	Returned to the company Employee stock option (right to buy)	−98,730			0 direct	Filing · EDGAR
May 14, 2008	Returned to the company Employee stock option (right to buy)	−59,238			0 direct	Filing · EDGAR
May 14, 2008	Returned to the company Employee stock option (right to buy)	−34,555			0 direct	Filing · EDGAR
May 14, 2008	Returned to the company Employee stock option (right to buy)	−33,333			0 direct	Filing · EDGAR
May 14, 2008	Returned to the company Employee stock option (right to buy)	−33,333			0 direct	Filing · EDGAR
May 14, 2008	Returned to the company Employee stock option (right to buy)	−33,333			0 direct	Filing · EDGAR
May 14, 2008	Returned to the company Employee stock option (right to buy)	−9,434			0 direct	Filing · EDGAR
May 14, 2008	Returned to the company Employee stock option (right to buy)	−9,434			0 direct	Filing · EDGAR
May 14, 2008	Returned to the company Employee stock option (right to buy)	−9,434			0 direct	Filing · EDGAR
May 14, 2008	Returned to the company Employee stock option (right to buy)	−13,021			0 direct	Filing · EDGAR
May 14, 2008	Returned to the company Employee stock option (right to buy)	−13,021			0 direct	Filing · EDGAR
May 14, 2008	Returned to the company Stock option (right to buy)	−2,500			0 direct	Filing · EDGAR
May 14, 2008	Returned to the company Stock option (right to buy)	−2,500			0 direct	Filing · EDGAR
May 14, 2008	Returned to the company Stock option (right to buy)	−5,000			0 direct	Filing · EDGAR
May 14, 2008	Returned to the company Stock option (right to buy)	−5,000			0 direct	Filing · EDGAR
May 14, 2008	Returned to the company Stock option (right to buy)	−5,000			0 direct	Filing · EDGAR
May 14, 2008	Returned to the company Stock option (right to buy)	−5,000			0 direct	Filing · EDGAR
May 14, 2008	Returned to the company Stock option (right to buy)	−5,000			0 direct	Filing · EDGAR
May 14, 2008	Returned to the company Stock option (right to buy)	−5,000			0 direct	Filing · EDGAR
May 14, 2008	Returned to the company Stock option (right to buy)	−5,834			0 direct	Filing · EDGAR
May 14, 2008	Returned to the company Stock option (right to buy)	−16,666			0 direct	Filing · EDGAR
May 14, 2008	Returned to the company Stock option (right to buy)	−2,500			0 direct	Filing · EDGAR
May 14, 2008	Returned to the company Restricted stock units	−5,000			0 direct	Filing · EDGAR
May 9, 2008	Tendered in a change of control	−32,014	$25.00	$800K	0 direct	Filing · EDGAR
May 5, 2008	Gift	−32,500			32,014 direct	Filing · EDGAR
Dec 11, 2007	Option or RSU exercised or converted	+59,238	$6.49	$384K	123,752 direct	Filing · EDGAR
Dec 11, 2007	Sale under a 10b5-1 plan	−59,238	$15.81	$936K	64,514 direct	Filing · EDGAR
Dec 11, 2007	Option or RSU exercised or converted Stock option (right to buy)	−59,238			0 direct	Filing · EDGAR
Sep 19, 2007	Sale under a 10b5-1 plan	−40,000	$10.68	$427K	64,514 direct	Filing · EDGAR
Sep 18, 2007	Option or RSU exercised or converted	+60,831	$8.44	$513K	144,514 direct	Filing · EDGAR
Sep 18, 2007	Sale under a 10b5-1 plan	−40,000	$10.33	$413K	104,514 direct	Filing · EDGAR
Sep 18, 2007	Option or RSU exercised or converted Stock option (right to buy)	−60,831			0 direct	Filing · EDGAR
Sep 17, 2007	Sale under a 10b5-1 plan	−10,000	$9.76	$98K	83,683 direct	Filing · EDGAR
Sep 5, 2007	Option or RSU exercised or converted	+30,000	$8.44	$253K	93,683 direct	Filing · EDGAR
Sep 5, 2007	Option or RSU exercised or converted Stock option (right to buy)	−30,000			60,831 direct	Filing · EDGAR
Sep 4, 2007	Sale under a 10b5-1 plan	−30,000	$10.20	$306K	63,683 direct	Filing · EDGAR
May 31, 2007	Grant or award from the company Restricted stock units	+5,000			5,000 direct	Filing · EDGAR
May 31, 2007	Grant or award from the company Stock option (right to buy)	+16,666			16,666 direct	Filing · EDGAR
May 1, 2007	Grant or award from the company Stock option (right to buy)	+5,834			5,834 direct	Filing · EDGAR
Feb 16, 2007	Open-market or private sale	−27,774	$11.24	$312K	93,683 direct	Filing · EDGAR
Jan 24, 2007	Option or RSU exercised or converted	+2,394	$6.34	$15K	121,457 direct	Filing · EDGAR
Jan 24, 2007	Option or RSU exercised or converted Stock option (right to buy)	−2,394			0 direct	Filing · EDGAR
Jan 23, 2007	Option or RSU exercised or converted	+7,225	$6.34	$46K	119,063 direct	Filing · EDGAR
Jan 23, 2007	Option or RSU exercised or converted Stock option (right to buy)	−7,225			2,394 direct	Filing · EDGAR
Nov 21, 2006	Option or RSU exercised or converted	+20,000	$6.34	$127K	131,838 direct	Filing · EDGAR
Nov 21, 2006	Open-market or private sale	−4,154	$11.46	$48K	127,684 direct	Filing · EDGAR
Nov 21, 2006	Open-market or private sale	−2,800	$11.45	$32K	124,884 direct	Filing · EDGAR
Nov 21, 2006	Open-market or private sale	−2,000	$11.44	$23K	122,884 direct	Filing · EDGAR
Nov 21, 2006	Open-market or private sale	−11,046	$11.41	$126K	111,838 direct	Filing · EDGAR
Nov 21, 2006	Option or RSU exercised or converted Stock option (right to buy)	−20,000			9,619 direct	Filing · EDGAR
Jul 1, 2006	Grant or award from the company Stock option (right to buy)	+5,000			5,000 direct	Filing · EDGAR
Jun 1, 2006	Grant or award from the company Stock option (right to buy)	+5,000			5,000 direct	Filing · EDGAR
May 1, 2006	Grant or award from the company Stock option (right to buy)	+5,000			5,000 direct	Filing · EDGAR
Jul 1, 2005	Grant or award from the company Stock option (right to buy)	+5,000			5,000 direct	Filing · EDGAR
Jun 1, 2005	Grant or award from the company Stock option (right to buy)	+5,000			5,000 direct	Filing · EDGAR
May 1, 2005	Grant or award from the company Stock option (right to buy)	+5,000			5,000 direct	Filing · EDGAR
Jul 1, 2004	Grant or award from the company Stock option (right to buy)	+2,500			2,500 direct	Filing · EDGAR
Jun 1, 2004	Grant or award from the company Stock option (right to buy)	+2,500			2,500 direct	Filing · EDGAR
May 1, 2004	Grant or award from the company Stock option (right to buy)	+2,500			2,500 direct	Filing · EDGAR
Mar 8, 2004	Discretionary trade in a company plan	−1,122	$18.27	$20K	111,838 direct	Filing · EDGAR

15 earlier transactions are in the filing list below.

Kosan Biosciences Director · filings 2004 to 2007

Date	Transaction	Shares	Price	Value	Held after	Source
May 25, 2007	Grant or award from the company Non-Statutory Stock Option (right to buy)	+6,000			6,000 direct	Filing · EDGAR
May 26, 2006	Grant or award from the company Non-Statutory Stock Option (right to buy)	+6,000			6,000 direct	Filing · EDGAR
May 26, 2005	Grant or award from the company Non-Statutory Stock Options (right to buy)	+6,000	$4.55	$27K	6,000 direct	Filing · EDGAR
May 27, 2004	Grant or award from the company Non-Statutory Stock Options (right to buy)	+6,000	$11.28	$68K	6,000 direct	Filing · EDGAR

All 139 Forms 3, 4, 5 and 144

Filed	Form	Company	Links
Jun 24, 2026	Form 4	BridgeBio Pharma BBIO	Filing · EDGAR
Jun 23, 2026	Form 4	BridgeBio Pharma BBIO	Filing · EDGAR
Jun 10, 2026	Form 4	Maze Therapeutics MAZE	Filing · EDGAR
May 6, 2026	Form 4	Maze Therapeutics MAZE	Filing · EDGAR
Nov 21, 2025	Form 4	Maze Therapeutics MAZE	Filing · EDGAR
Oct 27, 2025	Form 4	Maze Therapeutics MAZE	Filing · EDGAR
Sep 24, 2025	Form 4	Maze Therapeutics MAZE	Filing · EDGAR
Aug 12, 2025	Form 4	BridgeBio Pharma BBIO	Filing · EDGAR
Aug 11, 2025	Form 144	BridgeBio Pharma BBIO	Filing · EDGAR
Aug 8, 2025	Form 144	BridgeBio Pharma BBIO	Filing · EDGAR
Jun 30, 2025	Form 4	BridgeBio Pharma BBIO	Filing · EDGAR
Jun 24, 2025	Form 4	BridgeBio Pharma BBIO	Filing · EDGAR
Feb 4, 2025	Form 4	Maze Therapeutics MAZE	Filing · EDGAR
Jan 30, 2025	Form 3	Maze Therapeutics MAZE	Filing · EDGAR
Jun 25, 2024	Form 4	BridgeBio Pharma BBIO	Filing · EDGAR
Feb 21, 2024	Form 4	BridgeBio Pharma BBIO	Filing · EDGAR
Nov 20, 2023	Form 4	BridgeBio Pharma BBIO	Filing · EDGAR
Aug 18, 2023	Form 4	BridgeBio Pharma BBIO	Filing · EDGAR
Jun 23, 2023	Form 4	BridgeBio Pharma BBIO	Filing · EDGAR
May 18, 2023	Form 4	BridgeBio Pharma BBIO	Filing · EDGAR
Feb 21, 2023	Form 4	BridgeBio Pharma BBIO	Filing · EDGAR
Nov 18, 2022	Form 4	BridgeBio Pharma BBIO	Filing · EDGAR
Aug 18, 2022	Form 4	BridgeBio Pharma BBIO	Filing · EDGAR
Jun 24, 2022	Form 4	BridgeBio Pharma BBIO	Filing · EDGAR
May 18, 2022	Form 4	BridgeBio Pharma BBIO	Filing · EDGAR
Mar 15, 2022	Form 4	BridgeBio Pharma BBIO	Filing · EDGAR
Dec 6, 2021	Form 4	BridgeBio Pharma BBIO	Filing · EDGAR
Jun 30, 2021	Form 4	Pliant Therapeutics	Filing · EDGAR
Jun 22, 2021	Form 4	BridgeBio Pharma BBIO	Filing · EDGAR
Mar 3, 2021	Form 4	BridgeBio Pharma BBIO	Filing · EDGAR
Jan 26, 2021	Form 4	Population Health Investment	Filing · EDGAR
Nov 17, 2020	Form 3	Population Health Investment	Filing · EDGAR
Oct 19, 2020	Form 4	BridgeBio Pharma BBIO	Filing · EDGAR
Oct 1, 2020	Form 4	BridgeBio Pharma BBIO	Filing · EDGAR
Sep 29, 2020	Form 4	BridgeBio Pharma BBIO	Filing · EDGAR
Jun 4, 2020	Form 4	BridgeBio Pharma BBIO	Filing · EDGAR
Jun 2, 2020	Form 3	Pliant Therapeutics	Filing · EDGAR
Apr 7, 2020	Form 4	BridgeBio Pharma BBIO	Filing · EDGAR
Feb 12, 2020	Form 4	BridgeBio Pharma BBIO	Filing · EDGAR
Jan 16, 2020	Form 4	BridgeBio Pharma BBIO	Filing · EDGAR
Dec 16, 2019	Form 4	BridgeBio Pharma BBIO	Filing · EDGAR
Jul 3, 2019	Form 4	BridgeBio Pharma BBIO	Filing · EDGAR
Jun 27, 2019	Form 3	BridgeBio Pharma BBIO	Filing · EDGAR
Apr 1, 2019	Form 4	Portola Pharmaceuticals	Filing · EDGAR
Jan 4, 2019	Form 4	Portola Pharmaceuticals	Filing · EDGAR
Dec 19, 2018	Form 4	Portola Pharmaceuticals	Filing · EDGAR
Nov 16, 2018	Form 4	Portola Pharmaceuticals	Filing · EDGAR
Jun 22, 2018	Form 4	Global Blood Therapeutics	Filing · EDGAR
Jun 8, 2018	Form 4	Portola Pharmaceuticals	Filing · EDGAR
Feb 14, 2018	Form 5	Global Blood Therapeutics	Filing · EDGAR
Feb 14, 2018	Form 5/A	Global Blood Therapeutics	Filing · EDGAR
Oct 27, 2017	Form 4	Global Blood Therapeutics	Filing · EDGAR
Oct 5, 2017	Form 4	Global Blood Therapeutics	Filing · EDGAR
Jun 27, 2017	Form 4	Portola Pharmaceuticals	Filing · EDGAR
Jun 22, 2017	Form 4	Global Blood Therapeutics	Filing · EDGAR
Jun 22, 2017	Form 4	Global Blood Therapeutics	Filing · EDGAR
Jun 19, 2017	Form 4	Portola Pharmaceuticals	Filing · EDGAR
Mar 16, 2017	Form 4	Portola Pharmaceuticals	Filing · EDGAR
Mar 6, 2017	Form 4	Global Blood Therapeutics	Filing · EDGAR
Mar 3, 2017	Form 4	Portola Pharmaceuticals	Filing · EDGAR
Feb 14, 2017	Form 5	Global Blood Therapeutics	Filing · EDGAR
Dec 1, 2016	Form 4	MyoKardia	Filing · EDGAR
Nov 16, 2016	Form 4	Global Blood Therapeutics	Filing · EDGAR
Nov 7, 2016	Form 4	Global Blood Therapeutics	Filing · EDGAR
Jun 20, 2016	Form 4	Portola Pharmaceuticals	Filing · EDGAR
Jun 17, 2016	Form 4	Global Blood Therapeutics	Filing · EDGAR
Jun 9, 2016	Form 4	MyoKardia	Filing · EDGAR
Oct 28, 2015	Form 3	MyoKardia	Filing · EDGAR
Sep 18, 2015	Form 4	Portola Pharmaceuticals	Filing · EDGAR
Aug 13, 2015	Form 4	Global Blood Therapeutics	Filing · EDGAR
Aug 11, 2015	Form 3	Global Blood Therapeutics	Filing · EDGAR
Jul 14, 2015	Form 4	Portola Pharmaceuticals	Filing · EDGAR
Jun 29, 2015	Form 4	Portola Pharmaceuticals	Filing · EDGAR
Jun 17, 2015	Form 4	Portola Pharmaceuticals	Filing · EDGAR
Feb 23, 2015	Form 4	Portola Pharmaceuticals	Filing · EDGAR
Feb 17, 2015	Form 4	Portola Pharmaceuticals	Filing · EDGAR
Feb 13, 2015	Form 4	Portola Pharmaceuticals	Filing · EDGAR
Jan 28, 2015	Form 4	Portola Pharmaceuticals	Filing · EDGAR
Jan 27, 2015	Form 4	Portola Pharmaceuticals	Filing · EDGAR
Jul 1, 2014	Form 4	Portola Pharmaceuticals	Filing · EDGAR
Jun 20, 2014	Form 4	Portola Pharmaceuticals	Filing · EDGAR
Oct 23, 2013	Form 4	Portola Pharmaceuticals	Filing · EDGAR
Jun 7, 2013	Form 4	Portola Pharmaceuticals	Filing · EDGAR
May 21, 2013	Form 3	Portola Pharmaceuticals	Filing · EDGAR
Oct 17, 2011	Form 4	Cephalon	Filing · EDGAR
May 13, 2011	Form 4	Geron	Filing · EDGAR
May 12, 2011	Form 4	Cephalon	Filing · EDGAR
Mar 14, 2011	Form 4	Cephalon	Filing · EDGAR
Mar 14, 2011	Form 3	Cephalon	Filing · EDGAR
Jul 13, 2010	Form 4	Geron	Filing · EDGAR
May 21, 2010	Form 4	Geron	Filing · EDGAR
Jun 1, 2009	Form 4	Geron	Filing · EDGAR
May 29, 2008	Form 4	Geron	Filing · EDGAR
May 27, 2008	Form 4	Cytokinetics	Filing · EDGAR
May 15, 2008	Form 4	Millennium Pharmaceuticals	Filing · EDGAR
May 12, 2008	Form 4	Millennium Pharmaceuticals	Filing · EDGAR
May 7, 2008	Form 4	Millennium Pharmaceuticals	Filing · EDGAR
Jan 22, 2008	Form 4/A	Cytokinetics	Filing · EDGAR
Dec 13, 2007	Form 4	Millennium Pharmaceuticals	Filing · EDGAR
Sep 19, 2007	Form 4	Millennium Pharmaceuticals	Filing · EDGAR
Sep 6, 2007	Form 4	Millennium Pharmaceuticals	Filing · EDGAR
Jun 4, 2007	Form 4	Millennium Pharmaceuticals	Filing · EDGAR
May 30, 2007	Form 4	Kosan Biosciences	Filing · EDGAR
May 25, 2007	Form 4	Cytokinetics	Filing · EDGAR
May 24, 2007	Form 4	Geron	Filing · EDGAR
May 2, 2007	Form 4	Millennium Pharmaceuticals	Filing · EDGAR
Feb 20, 2007	Form 4	Millennium Pharmaceuticals	Filing · EDGAR
Jan 26, 2007	Form 4	Millennium Pharmaceuticals	Filing · EDGAR
Jan 5, 2007	Form 4	Geron	Filing · EDGAR
Nov 21, 2006	Form 4	Millennium Pharmaceuticals	Filing · EDGAR
Jul 5, 2006	Form 4	Millennium Pharmaceuticals	Filing · EDGAR
Jun 2, 2006	Form 4	Millennium Pharmaceuticals	Filing · EDGAR
May 31, 2006	Form 4	Kosan Biosciences	Filing · EDGAR
May 26, 2006	Form 4	Cytokinetics	Filing · EDGAR
May 26, 2006	Form 4	Geron	Filing · EDGAR
May 3, 2006	Form 4	Millennium Pharmaceuticals	Filing · EDGAR
Jul 19, 2005	Form 3	Geron	Filing · EDGAR
Jul 5, 2005	Form 4	Millennium Pharmaceuticals	Filing · EDGAR
Jun 2, 2005	Form 4	Millennium Pharmaceuticals	Filing · EDGAR
May 27, 2005	Form 4	Kosan Biosciences	Filing · EDGAR
May 20, 2005	Form 4	Cytokinetics	Filing · EDGAR
May 3, 2005	Form 4	Millennium Pharmaceuticals	Filing · EDGAR
Jul 27, 2004	Form 3/A	Cytokinetics	Filing · EDGAR
Jul 2, 2004	Form 4	Millennium Pharmaceuticals	Filing · EDGAR
Jun 2, 2004	Form 4	Millennium Pharmaceuticals	Filing · EDGAR
May 27, 2004	Form 4	Kosan Biosciences	Filing · EDGAR
May 4, 2004	Form 4	Millennium Pharmaceuticals	Filing · EDGAR
Apr 28, 2004	Form 3	Cytokinetics	Filing · EDGAR
Mar 10, 2004	Form 4	Millennium Pharmaceuticals	Filing · EDGAR
Feb 18, 2004	Form 4	Millennium Pharmaceuticals	Filing · EDGAR
Feb 11, 2004	Form 4	Millennium Pharmaceuticals	Filing · EDGAR
Feb 3, 2004	Form 4	Millennium Pharmaceuticals	Filing · EDGAR
Sep 8, 2003	Form 4	Millennium Pharmaceuticals	Filing · EDGAR
Sep 3, 2003	Form 4	Millennium Pharmaceuticals	Filing · EDGAR
May 19, 2003	Form 4	Millennium Pharmaceuticals	Filing · EDGAR
Mar 10, 2003	Form 4	Paper or text filing, not machine-readable	EDGAR
Dec 18, 2002	Form 4	Paper or text filing, not machine-readable	EDGAR
Nov 18, 2002	Form 4	Paper or text filing, not machine-readable	EDGAR
Oct 18, 2002	Form 4	Paper or text filing, not machine-readable	EDGAR

Every figure is as filed with the SEC on Forms 3, 4, 5 and 144. Holdings are the amounts reported after each person's latest filing at each company and can be out of date. Matching a Form 144 notice to Form 4 sales is SEC Tracker's inference from owner, company, dates and share counts, not something the filings state. Not investment advice. Not affiliated with the U.S. SEC.

Data on this page was fetched Nov 7, 2026, 1:32 AM ET. The filing on SEC.gov is the record.